[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370677-105":3,"doc-detail-370677-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-role-of-claudin-182-in-intrahepatic-cholangiocarcinoma","Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma","","Claudins are core tight-junction proteins that maintain cellular adhesion, regulate intercellular transport, and preserve cell polarity, and their dysregulation can drive signaling changes linked to epithelial cancer. This study evaluates the underexplored role of CLDN18.2 in intrahepatic cholangiocarcinoma and its association with clinical outcomes. Tissue from 182 patients undergoing curative surgery was analyzed for CLDN18.2 expression versus clinicopathologic variables and survival endpoints including OS, DFS, MeFS, and LRFS.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-role-of-claudin-182-in-intrahepatic-cholangiocarcinoma/370677/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-role-of-claudin-182-in-intrahepatic-cholangiocarcinoma/370677.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study on CLDN18.2 in intrahepatic cholangiocarcinoma?","Question",{"text":63,"@type":64},"To investigate the understudied role of CLDN18.2 in intrahepatic cholangiocarcinoma and assess how its expression relates to clinical outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients were included, and what treatment context was studied?",{"text":68,"@type":64},"The analysis used tissue samples from 182 patients who underwent curative surgery for intrahepatic cholangiocarcinoma.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about prognosis when CLDN18.2 was overexpressed?",{"text":72,"@type":64},"Overexpression of CLDN18.2 was associated with unfavorable clinical prognosis and adverse pathological features, including worse OS, DFS, LRFS, and MeFS in univariate and multivariate analyses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370677,1790535718,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8",8,"Virchows Archiv (2025) 486:1199–1210  \n[https://doi.org/10.1007/s00428-025-04081-x](https://doi.org/10.1007/s00428-025-04081-x)  \nPrognostic role of claudin‑18.2 in intrahepatic cholangiocarcinoma  \nYu‑Hsuan Kuo8,9,13 · Khaa Hoo Ong1,2,3 · Ding‑Ping Sun1 · Yu‑Feng Tian1 · Chia‑Ling Chou2,6 · Ti‑Chun Chan10,11 · Chung‑Hsi Hsing4,10 · Wan‑Shan Li2,3,5,12 · Chien‑Feng Li7,10,11,12 · Yow‑Ling Shiue3,7  \nReceived: 19 December 2024 / Revised: 13 March 2025 / Accepted: 15 March 2025 / Published online: 28 March 2025 © The Author(s) 2025  \nAbstract  \nClaudins are key components of tight junctions, essential for maintaining cellular adhesion, regulating intercellular molecule transport, and preserving cell polarity. Altered claudin expression can lead to tight junction dysfunction, potentially disrupting signaling pathways and contributing to the development of epithelial cancers. This study aims to explore the understudied role of CLDN18.2 in intrahepatic cholangiocarcinoma and its relationship with clinical outcomes. We analyzed tissue samples from 182 patients who underwent curative surgery for intrahepatic cholangiocarcinoma. Our research examined the relationship between CLDN18.2 expression and various clinical factors, including patient characteristics, pathological findings, and survival metrics such as overall survival (OS), disease-free survival (DFS), metastasis-free survival (MeFS), and local recurrence-free survival (LRFS) . Overexpression of CLDN18.2 showed significant associations with R1 resection (p = 0.032) and advanced T stage (p = 0.043) . Univariate analysis revealed that high CLDN18.2 expression was correlated with poorer OS (p = 0.0002), DFS (p \u003C 0.0001), LRFS (p \u003C 0.0001), and MeFS (p \u003C 0.0001) . Multivariate analysis further confirmed that high CLDN18.2 expression was independently associated with worse OS (p = 0.015), DFS (p\u003C 0.001), LRFS (p \u003C 0.001), and MeFS (p \u003C 0.001) . Overexpression of CLDN18.2 was associated with unfavorable clinical prognosis and adverse pathological features in intrahepatic cholangiocarcinoma. These findings suggest that CLDN18.2 could serve as a potential prognostic biomarker for intrahepatic cholangiocarcinoma.  \nKeywords CLDN18.2 · Biomarker · Intrahepatic cholangiocarcinoma  \n* Yow-Ling Shiue [shirley@imst.nsysu.edu.tw](shirley@imst.nsysu.edu.tw)  \n1 Division of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan  \n2 Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan 717, Taiwan  \n3 Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan  \n4 Department of Anesthesiology, Chi Mei Medical Center, Tainan 710, Taiwan  \n5 Department of Clinical Pathology, Chi Mei Medical Center, Tainan 710, Taiwan  \n6 Division of Colon and Rectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan  \n7 Institute of Precision Medicine, National Sun Yat-Sen University, Kaohsiung 804, Taiwan  \n8 Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan 71004, Taiwan  \n9 College of Pharmacy and Science, Chia Nan University, Tainan 71710, Taiwan  \n10 Department of Medical Research, Chi Mei Medical Center, Tainan 710, Taiwan  \n11 National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan  \n12 Trans-Omic Laboratory for Precision Medicine, Chi Mei Medical Center, Tainan 710, Taiwan  \n13 Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-Sen University, Kaohsiung 804, Taiwan  \nBackground  \nCholangiocarcinoma (CCA) encompasses a variety of malignant tumors originating in distinct regions of the biliary tract. These tumors are classified into three categories: intrahepatic (iCCA), distal CCA (dCCA), and perihilar (pCCA), each characterized by unique causes, risk factors, molecular profiles, prognoses, and treatment approaches. CCA is considered a rare disease; its global inciden","cbCaipRH3iqpcKXQ","https://ap.wps.com/l/cbCaipRH3iqpcKXQ","pdf",1690155,12,"English","# Abstract\n# Background\n## Cholangiocarcinoma overview\n## Epidemiology and risk factors\n## Treatment outcomes and need for biomarkers\n# Claudin-18.2 (CLDN18.2)","[{\"question\":\"What is the main purpose of the study on CLDN18.2 in intrahepatic cholangiocarcinoma?\",\"answer\":\"To investigate the understudied role of CLDN18.2 in intrahepatic cholangiocarcinoma and assess how its expression relates to clinical outcomes.\"},{\"question\":\"How many patients were included, and what treatment context was studied?\",\"answer\":\"The analysis used tissue samples from 182 patients who underwent curative surgery for intrahepatic cholangiocarcinoma.\"},{\"question\":\"What did the study find about prognosis when CLDN18.2 was overexpressed?\",\"answer\":\"Overexpression of CLDN18.2 was associated with unfavorable clinical prognosis and adverse pathological features, including worse OS, DFS, LRFS, and MeFS in univariate and multivariate analyses.\"}]","Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma | PDF",1790189727,30,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c607ada38434cb108be42cfca506bce7.webp",983,1305,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f05576c39ef2764e842487a157462bf.webp",982,1304,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/792184ffad202492f37420aade77711d.webp",981,1303,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/282ebef0499f0a91d885bfe7bfdcf808.webp",980,1301,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":98,"slug":146},"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]